Table 3. Comparisons of treatment outcome.

∮	Group	Baseline	1 year†	2 year††	p*	p**
ESR (mean±SD, mm/hr)	SPRA	55.2±32.3	22.0±18.6	21.5±17.2	<0.001	0.883
	SNRA	55.9±39.6	20.3±23.6	20.4±23.5	<0.001
CRP (mean±SD, mg/dL)	SPRA	2.5±3.9	1.6±4.0	1.6±3.9	0.038	0.439
	SNRA	3.6±5.2	1.5±2.4	1.3±1.9	0.041
28 TJC (mean±SD, number)	SPRA	3.3±2.7	0.5±1.0	0.5±0.8	<0.001	0.019
	SNRA	4.7±2.9	0.4±1.1	0.5±1.2	<0.001
28 SJC (mean±SD, number)	SPRA	2.9±2.3	0.6±1.2	0.5±0.9	<0.001	0.014
	SNRA	4.3±3.0	0.4±1.0	0.4±1.2	<0.001
DAS28-ESR(mean±SD)	SPRA	4.7±1.0	2.5±1.0	2.5±0.9	<0.001	0.895
	SNRA	5.1±1.0	2.1±1.0	2.1±1.3	<0.001

Statistical method: ∮linear mixed model *in-group comparison **inter-group comparison † number of patients with available 1 year followup data: SPRA (n = 158) SNRA (n = 29) †† number of patients with available 2 year followup data: SPRA (n = 111), SNRA (n = 19) ESR: erythrocyte sedimentation area, SD: standard deviation, SPRA: seropositive rheumatoid arthritis, SNRA: seronegative rheumatoid arthritis, CRP: C-reactive protein, 28 TJC: tender joint count in 28 joints assessed in disease activity score 28, 28 SJC: swollen joint count in 28 joints assessed in disease activity score 28, DAS28-ESR: disease activity score 28 base on ESR value